Testing Hepalatide for chronic hepatitis D
Part of Digestive system, Infections clinical trials.
This trial tests a new drug called Hepalatide for people with chronic hepatitis D (a liver infection). You must already have hepatitis B and be on a stable antiviral for it. The study checks if Hepalatide can safely lower HDV levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had hepatitis B for at least 6 months and are on a stable antiviral medication for hepatitis B for at least 3 months.
- You have tested positive for hepatitis D antibodies and have had detectable HDV RNA on two tests at least 3 months apart.
- Your ALT level (a liver enzyme) is between 1 and 10 times the upper limit of normal.
- You do not have severe liver disease (like advanced cirrhosis, fluid in the belly, or past bleeding from the esophagus).
- You are not pregnant, breastfeeding, and agree to use birth control during the study and for 3 months after.
- You have no serious health conditions like severe heart disease, uncontrolled diabetes, active cancer, or HIV/hepatitis A/C/E co-infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests whether a new monoclonal antibody (a lab-made protein that fights viruses) is safe and effective in people with chronic hepatitis D infection. Hepatitis D only occurs in people who also have hepatitis B, and this new treatment may help control the virus.
This study tests a new drug, Libevitug, for people with chronic hepatitis D (HDV). It aims to see if the drug can help control the virus and improve liver health.
This trial tests a new drug, GS-4321, for people with chronic hepatitis delta, a serious liver infection. It aims to see if the drug is safe and effective, and compares results in healthy volunteers and those with the virus.
This trial is testing treatments for people with chronic hepatitis D, a serious liver infection. If you have antibodies to the hepatitis D virus (HDV), you may be able to join and help find better ways to manage this condition.
This study tests a drug called bulevirtide for people with chronic hepatitis B and D co-infection. It aims to see if the drug is safe and effective, and to study biomarkers that may help predict how well it works.
This trial tests a drug called bulevirtide for people with chronic hepatitis B and D (HDV) co-infection. It looks at how the immune system and virus respond to treatment.
Hear when a new Hepatitis D, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.